You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Intermediate risk non-muscle invasive bladder cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer Trial (Cretostimogene Grenadenorepvec,

Not yet recruiting
  • Non Muscle Invasive Bladder Cancer
  • +3 more
  • Cretostimogene Grenadenorepvec
  • n-dodecyl-B-D-maltoside
  • (no location specified)
Oct 30, 2023

Bladder Cancer, Non-muscle Invasive Trial in Biel (Epirubicin, Mitomycin, Gemcitabine)

Recruiting
  • Bladder Cancer
  • Non-muscle Invasive
  • Biel, Switzerland
    Roland Seiler
Nov 17, 2022

Bladder Cancer Trial in Mansoura (Intravesical Bcg, Intravesical chemo (epirubicin))

Recruiting
  • Bladder Cancer
  • Intravesical Bcg
  • Intravesical chemotherapy (epirubicin)
  • Mansoura, DK, Egypt
    Mansoura Urology and Nephrology Center
Dec 21, 2021

Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Not yet recruiting
  • Non-muscle-invasive Bladder Cancer
    • (no location specified)
    Apr 11, 2023

    Bladder Cancer Trial in Jinan (Pseudomonas aeruginosa)

    Recruiting
    • Bladder Cancer
    • Pseudomonas aeruginosa
    • Jinan, Shandong, China
      Qilu hospital
    Jul 26, 2023

    Non-muscle-invasive Bladder Cancer Trial in Cairo (BCG, Gemcitabine)

    Recruiting
    • Non-muscle-invasive Bladder Cancer
    • Cairo, Egypt
      Mohamed Fawzy Salman
    Nov 19, 2022

    Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202, Epirubicin Hydrochloride)

    Recruiting
    • Non-muscle Invasive Bladder Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 21, 2022

    Bladder Cancer Trial in San Antonio (Intervention, Control)

    Completed
    • Bladder Cancer
    • Intervention
    • Control
    • San Antonio, Texas
      The University of Texas Health Science Center
    Jun 9, 2021

    Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in United States (UGN-102)

    Active, not recruiting
    • Bladder Cancer
    • +2 more
    • Homewood, Alabama
    • +4 more
    Dec 15, 2022

    Bladder Cancer, Bladder Cancer Recurrent, Tumor Recurrence Trial (Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus

    Not yet recruiting
    • Bladder Cancer
    • +5 more
    • Bacillus Calmette-Guerin: Strain Russian BCG-I
    • Bacillus Calmette-Guerin: Strain TICE
    • (no location specified)
    Apr 7, 2022

    Bladder Cancer Trial in Madison (Qapzola, Placebo)

    Terminated
    Has Results
    • Bladder Cancer
    • Madison, Wisconsin
      University of Wisconsin
    Aug 30, 2021

    Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202 in combination with Epirubicin, Placebo in combination with

    Active, not recruiting
    • Non-muscle Invasive Bladder Cancer
    • APL-1202 in combination with Epirubicin
    • Placebo in combination with Epirubicin
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 21, 2022

    Bladder Cancer Patients to Detect Recurrences After TURB Earlier

    Active, not recruiting
    • Non-muscle-invasive Bladder Cancer
    • Xpert Bladder Cancer Monitor
    • Salzburg, Austria
    • +12 more
    Aug 3, 2021

    Predicting BCG Response

    Recruiting
    • Bladder Cancer
      • Los Angeles, California
        Cedars-Sinai Medical Center
      Mar 7, 2022

      Non-muscle-invasive Bladder Cancer Trial (Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test)

      Not yet recruiting
      • Non-muscle-invasive Bladder Cancer
      • Cystoscopy
      • +2 more
      • (no location specified)
      Apr 4, 2023

      Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Ankara (Nerve Stimulator-guided Obturator Nerve Block)

      Completed
      • Bladder Cancer Stage 0
      • Bladder Cancer Stage I
      • Nerve Stimulator-guided Obturator Nerve Block
      • Ankara, Altindag, Turkey
        Ankara Training and Research Hospital
      May 10, 2021

      High-risk Non-muscle Invasive Bladder Cancer Trial (SHR-2005)

      Not yet recruiting
      • High-risk Non-muscle Invasive Bladder Cancer
      • (no location specified)
      Oct 25, 2023

      Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

      Not yet recruiting
      • Non-muscle Invasive Bladder Cancer
      • Chengdu, Sichuan, China
        West China Hospital
      Aug 10, 2023

      Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder

      Not yet recruiting
      • Non-muscle-invasive Bladder Cancer
      • +2 more
      • PDD-TURBT with hexaminolevulinate (Hexvix®)
      • Power Led Saphira (TM) from KARL STORZ
      • (no location specified)
      Jul 24, 2023

      Non-Muscle- Invasive Bladder Cancer Trial (Durvalumab, BCG)

      Not yet recruiting
      • Non-Muscle- Invasive Bladder Cancer
      • Durvalumab
      • BCG
      • (no location specified)
      Jul 5, 2023

      Neutrophils to Lymphocytes Ratio in Predicting Response to BCG

      Completed
      • Urinary Bladder Cancer
      • +4 more
      • Neutrophil to lymphocyte ratio
      • Cairo, Egypt
        Ain Shams university
      Jul 15, 2023

      Non-muscle-invasive Bladder Cancer Trial in Zagreb (Gemcitabine 1000 mg, Docetaxel 37.5g)

      Active, not recruiting
      • Non-muscle-invasive Bladder Cancer
      • Gemcitabine 1000 mg, Docetaxel 37.5g
      • Zagreb, Croatia
        University Hospital Centre Zagreb
      Jan 20, 2023

      Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

      Not yet recruiting
      • Non-Muscle Invasive Bladder Cancer
      • HER2
      • (no location specified)
      Jul 16, 2023

      Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder Trial in Worldwide (UGN-102)

      Recruiting
      • Bladder Cancer
      • +2 more
      • Tucson, Arizona
      • +76 more
      Jul 13, 2022

      Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive

      Recruiting
      • Non Muscle Invasive Bladder Cancer
      • N803 plus Bacillus Calmette-Guerin (BCG)
      • Honolulu, Hawaii
        Island Urology
      Aug 7, 2023